- Report
- August 2025
- 185 Pages
Global
From €4084EUR$4,500USD£3,488GBP
- Report
- May 2026
- 30 Pages
Global
From €2496EUR$2,750USD£2,132GBP
- Report
- April 2026
- 225 Pages
Global
From €7252EUR$7,990USD£6,194GBP
- Report
- March 2026
- 150 Pages
Global
From €3404EUR$3,750USD£2,907GBP
- Report
- November 2025
- 200 Pages
Global
From €7216EUR$7,950USD£6,163GBP
- Report
- July 2026
- 365 Pages
Global
From €5310EUR$5,850USD£4,535GBP
- Report
- May 2026
- 150 Pages
Global
From €2450EUR$2,699USD£2,092GBP
- Report
- May 2026
- 400 Pages
Global
From €4492EUR$4,949USD£3,836GBP
- Drug Pipelines
- May 2026
- 150 Pages
Global
From €2531EUR$2,789USD£2,162GBP
- Report
- April 2026
- 146 Pages
Global
From €2722EUR$2,999USD£2,325GBP
€3630EUR$3,999USD£3,100GBP
- Report
- April 2026
- 150 Pages
Global
From €2722EUR$2,999USD£2,325GBP
€3630EUR$3,999USD£3,100GBP
- Report
- July 2026
- 115 Pages
Global
From €4311EUR$4,750USD£3,682GBP
- Report
- May 2026
- 110 Pages
Global
From €4311EUR$4,750USD£3,682GBP
- Report
- January 2026
- 120 Pages
Global
From €4311EUR$4,750USD£3,682GBP
- Report
- January 2026
- 120 Pages
Global
From €16332EUR$17,995USD£13,950GBP
- Report
- September 2025
- 81 Pages
Global
From €16332EUR$17,995USD£13,950GBP
- Report
- July 2026
- 160 Pages
Global
From €3767EUR$4,150USD£3,217GBP
- Report
- October 2025
- 160 Pages
Global
From €2868EUR$3,160USD£2,450GBP
€3585EUR$3,950USD£3,062GBP
- Report
- August 2025
- 150 Pages
Global
From €2868EUR$3,160USD£2,450GBP
€3585EUR$3,950USD£3,062GBP
- Report
- September 2025
- 150 Pages
Global
From €4402EUR$4,850USD£3,760GBP

The JAK Inhibitor market is a subset of the larger Immune Disorders Drugs market. JAK Inhibitors are a type of drug used to treat a variety of immune-related disorders, such as rheumatoid arthritis, psoriasis, and Crohn's disease. These drugs work by blocking the activity of Janus kinase (JAK) enzymes, which are involved in the body's inflammatory response. JAK Inhibitors are typically taken orally, and are often used in combination with other medications.
The JAK Inhibitor market is highly competitive, with a number of large pharmaceutical companies vying for market share. Some of the major players in the market include AbbVie, Pfizer, Novartis, and Johnson & Johnson. Other companies, such as Celgene, Merck, and Eli Lilly, are also active in the market. Show Less Read more